131 related articles for article (PubMed ID: 35037102)
1. Mammographic density to predict response to neoadjuvant systemic breast cancer therapy.
Di Cosimo S; Depretto C; Miceli R; Baili P; Ljevar S; Sant M; Cappelletti V; Folli S; Gennaro M; De Braud FG; Bianchi G; Vingiani A; Pruneri G; Marchianò A; La Rocca E; De Santis MC; Scaperrotta GP
J Cancer Res Clin Oncol; 2022 Apr; 148(4):775-781. PubMed ID: 35037102
[TBL] [Abstract][Full Text] [Related]
2. Mammographic density as an image-based biomarker of therapy response in neoadjuvant-treated breast cancer patients.
Skarping I; Förnvik D; Heide-Jørgensen U; Sartor H; Hall P; Zackrisson S; Borgquist S
Cancer Causes Control; 2021 Mar; 32(3):251-260. PubMed ID: 33377172
[TBL] [Abstract][Full Text] [Related]
3. Mammographic density is a potential predictive marker of pathological response after neoadjuvant chemotherapy in breast cancer.
Skarping I; Förnvik D; Sartor H; Heide-Jørgensen U; Zackrisson S; Borgquist S
BMC Cancer; 2019 Dec; 19(1):1272. PubMed ID: 31888552
[TBL] [Abstract][Full Text] [Related]
4. Mammographic density changes during neoadjuvant breast cancer treatment: NeoDense, a prospective study in Sweden.
Skarping I; Förnvik D; Heide-Jørgensen U; Sartor H; Hall P; Zackrisson S; Borgquist S
Breast; 2020 Oct; 53():33-41. PubMed ID: 32563178
[TBL] [Abstract][Full Text] [Related]
5. The association between breast density and breast cancer pathological response to neoadjuvant chemotherapy.
Cullinane C; Brien AO; Shrestha A; Hanlon EO; Walshe J; Geraghty J; Evoy D; McCartan D; McDermott E; Prichard R
Breast Cancer Res Treat; 2022 Jul; 194(2):385-392. PubMed ID: 35606616
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of tumor-infiltrating lymphocytes and mammographic density as predictors of response to neoadjuvant systemic therapy in breast cancer.
Landén AH; Chin K; Kovács A; Holmberg E; Molnar E; Stenmark Tullberg A; Wärnberg F; Karlsson P
Acta Oncol; 2023 Dec; 62(12):1862-1872. PubMed ID: 37934084
[TBL] [Abstract][Full Text] [Related]
7. Human Epidermal Growth Factor 2-positive Breast Cancer with Mammographic Microcalcification: Relationship to Pathologic Complete Response after Neoadjuvant Chemotherapy.
Mazari FAK; Sharma N; Dodwell D; Horgan K
Radiology; 2018 Aug; 288(2):366-374. PubMed ID: 29786482
[TBL] [Abstract][Full Text] [Related]
8. Associations between mammographic density and tumor characteristics in Chinese women with breast cancer.
Li E; Guida JL; Tian Y; Sung H; Koka H; Li M; Chan A; Zhang H; Tang E; Guo C; Deng J; Hu N; Lu N; Gierach GL; Li J; Yang XR
Breast Cancer Res Treat; 2019 Sep; 177(2):527-536. PubMed ID: 31254158
[TBL] [Abstract][Full Text] [Related]
9. Is mammographic density a marker of breast cancer phenotypes?
Kanbayti IH; Rae WID; McEntee MF; Al-Foheidi M; Ashour S; Turson SA; Ekpo EU
Cancer Causes Control; 2020 Aug; 31(8):749-765. PubMed ID: 32410205
[TBL] [Abstract][Full Text] [Related]
10. Mammographic assessment of breast density as a tool for predicting the response to neoadjuvant therapy in breast cancer patients.
Lisencu LA; Roman A; Paşca A; Irimie A; Lisencu C; Negrutiu M; Fetica B; Cismaru A; Balacescu O; Tudoran O; Lisencu C
Med Pharm Rep; 2024 Jan; 97(1):43-55. PubMed ID: 38344331
[TBL] [Abstract][Full Text] [Related]
11. Changes in Automated Mammographic Breast Density Can Predict Pathological Response After Neoadjuvant Chemotherapy in Breast Cancer.
Ahn JH; Go J; Lee SJ; Kim JY; Park HS; Kim SI; Park BW; Park VY; Yoon JH; Kim MJ; Park S
Korean J Radiol; 2023 May; 24(5):384-394. PubMed ID: 37133209
[TBL] [Abstract][Full Text] [Related]
12. Association between mammographic density and basal-like and luminal A breast cancer subtypes.
Razzaghi H; Troester MA; Gierach GL; Olshan AF; Yankaskas BC; Millikan RC
Breast Cancer Res; 2013; 15(5):R76. PubMed ID: 24008056
[TBL] [Abstract][Full Text] [Related]
13. Mammographic breast density: Predictive value for pathological response to neoadjuvant chemotherapy in breast cancer patients.
Elsamany S; Alzahrani A; Abozeed WN; Rasmy A; Farooq MU; Elbiomy MA; Rawah E; Alsaleh K; Abdel-Aziz NM
Breast; 2015 Oct; 24(5):576-81. PubMed ID: 26071795
[TBL] [Abstract][Full Text] [Related]
14. Mammographic density in relation to breast cancer recurrence and survival in women receiving neoadjuvant chemotherapy.
Zdanowski A; Sartor H; Feldt M; Skarping I
Front Oncol; 2023; 13():1177310. PubMed ID: 37388229
[TBL] [Abstract][Full Text] [Related]
15. Exploring the added value of pretherapeutic MR descriptors in predicting breast cancer pathologic complete response to neoadjuvant chemotherapy.
Malhaire C; Selhane F; Saint-Martin MJ; Cockenpot V; Akl P; Laas E; Bellesoeur A; Ala Eddine C; Bereby-Kahane M; Manceau J; Sebbag-Sfez D; Pierga JY; Reyal F; Vincent-Salomon A; Brisse H; Frouin F
Eur Radiol; 2023 Nov; 33(11):8142-8154. PubMed ID: 37318605
[TBL] [Abstract][Full Text] [Related]
16. Association between mammographic features and response to neoadjuvant chemotherapy in locally advanced breast carcinoma.
Castaneda CA; Flores R; Rojas K; Flores C; Castillo M; Milla E
Hematol Oncol Stem Cell Ther; 2014 Dec; 7(4):149-56. PubMed ID: 25300565
[TBL] [Abstract][Full Text] [Related]
17. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
[TBL] [Abstract][Full Text] [Related]
18. Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial.
Di Cosimo S; Porcu L; Agbor-Tarh D; Cinieri S; Franzoi MA; De Santis MC; Saura C; Huober J; Fumagalli D; Izquierdo M; Piccart M; Daidone MG; de Azambuja E
Breast Cancer Res; 2020 Oct; 22(1):115. PubMed ID: 33109233
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the association between mammographic density and the risk of breast cancer using Quantra software and the BI-RADS classification.
Wang JM; Zhao HG; Liu TT; Wang FY
Medicine (Baltimore); 2020 Nov; 99(46):e23112. PubMed ID: 33181680
[TBL] [Abstract][Full Text] [Related]
20. Mammographic density and structural features can individually and jointly contribute to breast cancer risk assessment in mammography screening: a case-control study.
Winkel RR; von Euler-Chelpin M; Nielsen M; Petersen K; Lillholm M; Nielsen MB; Lynge E; Uldall WY; Vejborg I
BMC Cancer; 2016 Jul; 16():414. PubMed ID: 27387546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
